Halozyme Therapeutics (LTS:0J2O) Current Accrued Expense : $130 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics Current Accrued Expense?

Halozyme Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2025 was $130 Mil.

Halozyme Therapeutics's quarterly Current Accrued Expense increased from Sep. 2024 ($96 Mil) to Dec. 2024 ($129 Mil) and increased from Dec. 2024 ($129 Mil) to Mar. 2025 ($130 Mil).

Halozyme Therapeutics's annual Current Accrued Expense increased from Dec. 2022 ($100 Mil) to Dec. 2023 ($101 Mil) and increased from Dec. 2023 ($101 Mil) to Dec. 2024 ($129 Mil).

Halozyme Therapeutics Current Accrued Expense Historical Data

The historical data trend for Halozyme Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Current Accrued Expense Chart

Halozyme Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

20.48

24.44

99.76

100.68

128.85

Halozyme Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															118.31	117.93	96.42	128.85	130.31

Halozyme Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Halozyme Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

HALO:USA RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Headlines

No Headlines